Seventy percent of women with ovarian cancer develop resistance to cisplatin, contributing to persistently high mortality rates. Understanding the mechanisms behind this resistance is crucial for deve
Targeting classical end-joining signaling pathway might be a potential therapeutic strategy to overcome the chemotherapeutic drug resistance and increase the potency of cancer treatment To investigate
